Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone

EU orphan designation number: EU/3/14/1242   
Active ingredient: 3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone
Indication: Treatment of Rett syndrome
Sponsor: Neurolixis SAS
2 rue Georges Charpak l'Arobase, le Causse Espace d'Entreprise, 81290 Labruguiere, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/02/2014 Orphan designation EMA/OD/163/13 (2014)1217 of 19/02/2014
2/10/2018 Transfer of orphan designation EMA/OD/163/13/T/01 (2018)6436 of 27/09/2018